

Thank you for joining the Optum CE webinar:
The New Era of Weight Loss Medications is Here

- The webinar will begin at 2:00 p.m. ET
- **All attendees are in listen-only mode. All microphones are muted and there is currently no audio to be heard.**
- Audio is only available through your computer audio. No dial-in number is available.
- If others in your office want to join the webinar, have them register with the course link at:
workcompauto.optum.com/resources/continuing-education
(Do not share your webinar link with others. It is unique to you.)
- CE credits are only available for those who qualify during the live version of this webinar held from 2:00-3:00 p.m. ET on 11/06/2024.

On24 system requirements:

- Windows 7+ (Microsoft Edge, latest Internet Explorer, Firefox, or Chrome)
- Apple Mac OS 10.10+ (*Latest Firefox, Safari, or Chrome)
- Android 6.x (Chrome browser only)
- Apple iOS (*Latest version, Safari Browser Only)


*Official support for the "latest" version of a newly released browser, among those noted above, will be added within 8 weeks of public release. Until then, the previous version will continue to be supported instead.

If you are using an unsupported version of a Windows, Mac, or Linux operating system, you may experience difficulty in viewing and/or listening to the event.



The new era of weight-loss medications is here

November 6, 2024



Questions about continuing education credits

- If you have any questions regarding your continuing education credits received from Optum webinars, please contact rosters@ceuinstitute.net.
- CE credits are only available for those who qualify during the live version of this webinar held on 11/06/2024 from 2:00-3:00 p.m. ET.

This course has been approved for 1-hour of CE for the following license types: Pre-approved Adjuster (AK, AL, AR, CA, DE, FL, GA, ID, IN, KY, LA, MS, MT, NC, NH, NM, NV, OK, OR, TX, UT, WV, WY); National Certified Case Manager (CCM); National Nurse; Certified Disability Management Specialists (CDMS); and Certified Rehabilitation Counselor (CRC). For states that do not require prior approval, the adjuster is responsible for submitting their attendance certificate to the appropriate state agency to determine if continuing education credits can be applied.

This course has NOT been approved for WA adjuster or Certified Medicare Secondary Payer (CMSP) credits.

To receive continuing education credit

- 1 Attend the live version of the webinar.
- 2 Remain logged on for the entire webinar.
- 3 Answer all three poll questions. (Questions appear on the screen and will be read aloud.)



Example poll question?


A. Option 1

B. Option 2

C. Option 3

Submit

Use the Submit button on your screen



Q&A

Enter your question

Submit

Send your answer in the Q&A panel

To receive continuing education credit

Submit for your CE credits via the email link sent to you by the CEU Institute. The email:

- Will be sent within 48 hours after the webinar ends to those who qualified for CE credit
- Contains a submission link that you should respond to within 72 hours of receiving

Greetings,

Thank you for attending the event above.

The attendance reports show that you should be awarded credit for this program.

- To ensure your state license information is correct, **we ask that you complete the link below promptly.**
- We will submit your credits to the state board/s and send your certificate shortly.

To Receive Credit:

1. Click on the **Credit Submission Link** below (if it does not open when clicked on, copy the URL and paste in your web browser).
2. Complete the information requested hit submit at the end.
3. **Link is open for 72 business hours only.**

*Sometimes due to large volume of submissions, you will get an error message. If this happens wait 10 minutes and try again.

Credit Submission Link (past the link below into your browser)

[LINK FOR PROGRAM WILL APPEAR HERE](#)

Please let me know if you have any questions. Thank you.

Kindest Regards,

Compliance Support Team



144 W Crystal Lake Ave Unit 1010 | Lake Mary, FL 32746

Office: 407.324.0500_x 206 | Fax: 407.302.2185

rosters@ceuinstitute.net | www.ceuinstitute.net

CE submission email/link from the CEU Institute additional info

- Each state/agency has strict requirements on how long you have to submit for your CE credits. If you miss the 72-hour window, you may not be able to receive the CE credits.
- Check your junk mail as sometimes the email lands there. (Add rosters@ceuinstitute.net email to your contacts.)
- If you will be out of the office and will miss the 72-hour window, send an email to ceprogram@optum.com to let us know.
- Once you submit for your CE credits, it can take up to 30 days to process before credits are reported or you receive a certificate.
- If you have questions about your CE credits for this course or any other Optum CE webinar, please contact the CEU Institute at rosters@ceuinstitute.net.




The screenshot shows the CEU Institute registration form. At the top is the CEU Institute logo. Below it is a header for the form: "Date / Organization / Topic". The form fields are as follows:

- Name***: Two input fields for "First Name" and "Last Name".
- City***: One input field.
- State***: One input field.
- Email***: One input field.
- Confirm Email***: One input field.
- License Type***: A list of checkboxes for "Adjuster", "CCM", "CDMS", "CNSP", "CRC", and "Nurse".

Ask a question

- Questions for speakers will be answered as time allows or we will respond via email after the webinar.
- We will answer questions as quickly as possible during the webinar but please expect some delay.



The image shows a window titled "Q&A" with a large, empty text input area. Below the input area is a text box containing the placeholder text "Enter your question" and an orange "Submit" button.

Experiencing technical difficulties?

- Refresh your screen
 - You may need to do this after poll questions.
- Make sure your speakers are turned up and, if used, headphones are placed properly
 - There is no dial in number for this webinar. Audio is through your computer only.
- Switch web browsers
 - Chrome tends to work well
- Log off and log back in
- Log out of your company's VPN

Still having technical issues?

- Let us know if you experience an issue that causes you to:
 - Miss a poll question
 - Have audio problems
 - Log out
 - Any other technical issue
- Send a message using the webinar controls question panel or email ceprogram@optum.com.
- The sooner we know about an issue, the faster we can take the steps needed to help you qualify for the continuing education credits you require.

This course has been approved for 1-hour of CE for the following license types: Pre-approved Adjuster (AK, AL, AR, CA, DE, FL, GA, ID, IN, KY, LA, MS, MT, NC, NH, NM, NV, OK, OR, TX, UT, WV, WY); National Certified Case Manager (CCM); National Nurse; Certified Disability Management Specialists (CDMS); and Certified Rehabilitation Counselor (CRC) for CE accreditation. For states that do not require prior approval, the adjuster is responsible for submitting their attendance certificate to the appropriate state agency to determine if continuing education credits can be applied.

This course has NOT been approved for WA adjuster or Certified Medicare Secondary Payer (CMSP) credits.



HOW TO QUALIFY FOR CREDITS

1. Attend the LIVE version of this webinar. If you log in at any other time, you will be watching a recording and you cannot qualify for CE credit.
2. Remain logged in for the entire hour. If you get kicked out of the system just log back in, we track your total time.
3. Submit answers to all three poll questions. Use the Submit button on screen. If that doesn't work, submit your answer in the Q&A box.
4. The CEU Institute will email you within 24-48 hours after the webinar. It contains a link to submit for your credits. Please complete this task within 72 hours.

Presentation



The new era of weight-loss medications is here

Webinar # 2024



Related Content

- Resources and Troubleshooting (opens in new window)
- PDF of the Presentation (opens in new window)
- A PDF copy of the presentation and a recording of this webinar will be available on the Optum website the day after the live webinar. (opens in new window)

Q&A

Enter your question

Submit

If you are having technical difficulties with audio or the visuals try the following:

Refresh your screen

Make sure your speakers are turned up and, if used, headphones are placed properly

There is no dial in number for this webinar. Audio is through your computer only.

Switch web browsers (Chrome works well)

Log off and log back in



Reactions



Disclosure

No planner, presenter or content expert has a conflicting interest affecting the delivery of this continuing education activity. Optum does not receive any commercial advantage nor financial remittance through the provided continuing education activities.

Medical disclaimer

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, new treatment options and approaches are developed. The authors have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at time of publication.

However, in view of the possibility of human error or changes in medical sciences, neither Optum nor any other party involved in the preparation or publication of this work warrants the information contained herein is in every respect accurate or complete and are not responsible for errors or omissions or for the results obtained from the use of such information. Readers are encouraged to confirm the information contained herein with other sources.

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the Food and Drug Administration (FDA). We do not promote the use of any agent outside of approved labeling. Statements made in this presentation have not been evaluated by the FDA.

Disclaimer

The display or graphic representation of any product or description of any product or service within this presentation shall not be construed as an endorsement of that product by the presenter or any accrediting body. Rather, from time to time, it may facilitate the learning process to include/use such products or services as a teaching example.


Accreditation of this continuing education activity refers to recognition of the educational activity only and does not imply endorsement or approval of those products and/or services by any accrediting body.

CE credits for this course are administered by the CEU Institute. If you have any issues or questions regarding your credits, please contact rosters@ceuinstitute.net.



The new era of weight-loss medications is here

November 6, 2024



Presenters




Kelly Kaufman, RPh
Clinical Pharmacist Liaison



Robert Hall, MD
Optum Corporate Medical Director


Obesity in America and the American workforce



of adults have obesity

49.9%
African
Americans

45.6%
Latino



In 2022, **19** states had obesity rates above **31%**, up from 16 states in 2021

Recently developed weight-loss medications (GLP-1 agonists)

1. Zepbound® (tirzepatide)
2. Wegovy® (semaglutide)
3. Saxenda® (liraglutide)



GLP-1 agonists as weight-loss medications

How GLP-1 agonists work



Intended to be used
lifelong for diabetes



Curbing hunger



Controlling blood sugar by
stimulating the production
of insulin



Slowing movement of
food from stomach into
small intestine

Dosing, frequency, formulation, and compliance considerations



Potential side effects of GLP-1 agonists

- Loss of appetite
- Fatigue
- Nausea and slowed gastric (stomach) emptying
- Hair loss
- Depression
- Suicidal ideation
- Pancreatitis and kidney issues
- Optic neuritis (inflammation of the optic nerve to the eye)
- Rapid weight loss resulting in...
 - Muscle atrophy
 - Bone loss
 - Negative impact on workforce
- **Black box warning: thyroid cancer (medullary)**

Possible drug- drug interactions with other medications



Potential scenarios for GLP-1 use in workers' compensation



Presurgical

- Obese worker injured on the job
- Diagnosed with a torn ACL in the knee
- Obesity can affect recovery after ACL reconstruction surgery
- Surgery delayed until worker can lose weight
- GLP-1 agonist prescribed to assist with weight loss



Post-injury

- Healthy worker injured on the job
- Developed a spinal cord injury
- Obesity can develop following severe debilitating injuries, i.e., spinal cord injuries, traumatic brain injuries
- New-onset diabetes (related to weight gain) is determined to be compensable in the claim
- GLP-1 agonist prescribed to assist with weight loss and diabetes management

Poll #1

- You must answer **all three poll questions** to qualify for CE credit.
- If you cannot see the poll question, **it will be read aloud multiple times.**
- After the poll question, you may need to refresh your screen

To submit your poll question answer:

Use the Submit button on your screen



Example poll question?

A. Option 1


B. Option 2

C. Option 3

Submit

OR

Send your answer in the Q&A panel



Q&A

Enter your question

Submit

Presumption in workers' comp claims



Risks with compounding of GLP-1 agonists



Financial considerations for GLP-1 agonists

High-cost



Complex
manufacturing
process



Patent protected



Generics not yet
available


High-cost



Group health challenges



Coverage as a hiring incentive



Prior authorization process

Determining the duration of treatment with GLP-1 agonists



How long will injured workers need to stay on their GLP-1?

1. Group health: GLP-1s are cost prohibitive
2. Assessment periods
 - a. How often should the injured worker be reassessed?
 - b. What should a reassessment involve?



Additional weight-loss strategies and support

1. Dietary modifications and possible nutritional supplements
2. Routine exercise program
3. Non GLP-1 medications for diabetes and weight loss
4. Counseling and behavioral therapy



Poll #2

- You must answer **all three poll questions** to qualify for CE credit.
- If you cannot see the poll question, **it will be read aloud multiple times.**
- After the poll question, you may need to refresh your screen

To submit your poll question answer:

Use the Submit button on your screen



Example poll question?

A. Option 1


B. Option 2

C. Option 3

Submit

OR

Send your answer in the Q&A panel



Q&A

Enter your question

Submit

Setting reasonable goals for claims with GLP-1 agonists



Pipeline of future weight-loss medications

2025

Oral Semaglutide (*Oral*)

GLP-1 agonist

Novo Nordisk

(Novo Nordisk has been silent on updated plans for Rybelsus for obesity – unclear when/if they will file for the new indication)

2026

Cagrilintide / semaglutide **(CagriSema)** (*SC Injection*)

GLP-1/amylin agonist

Novo Nordisk | Early 2026

Orforglipron (*Oral*)

GLP-1 agonist

Eli Lilly | 4Q2026

2027

Survodutide (*SC Injection*)

GLP-1/glucagon agonist

Boehringer Ingelheim | 2Q2027

Retatrutide (*SC Injection*)

GLP-1/glucagon agonist

Eli Lilly | 4Q2027

Pipeline of future weight-loss medications

2028 or later*

**Maridebart cafraglutide
(MariTide)** (SC Injection –monthly)

GLP-1 agonist, GIP antagonist

Amgen

GSBR-1290 (Oral)

GLP-1 agonist

Structure Therapeutics

VK2735 (Oral)

GLP-1 agonist

Viking Therapeutics

RG-6641 (SC Injection)

GLP-1/GIP agonist

Roche

S-309309 (Oral)

MGAT2 inhibitor

Shionogi

K-757, K-833 (Oral)

Nutrient receptor agonist

Kallyope

Pemvidutide (SC Injection)

GLP-1/Glucagon agonist

Altimune

Poll #3

- You must answer **all three poll questions** to qualify for CE credit.
- If you cannot see the poll question, **it will be read aloud multiple times.**
- After the poll question, you may need to refresh your screen

To submit your poll question answer:

Use the Submit button on your screen



Example poll question?

A. Option 1


B. Option 2

C. Option 3

Submit

OR

Send your answer in the Q&A panel



Q&A

Enter your question

Submit

Conclusions and key takeaways

Key takeaways

1. Adjudication controls (i.e., hard block vs. soft block with clinical review, prior auth/UR, etc.)
2. Defined length of treatment with GLP-1 agonist
3. Return-to-work if weight loss is successful
4. Possible legal/court determinations for lifelong treatment
5. Agreement with injured worker on defined endpoint
6. Potential effects of GLP-1 cessation
7. Whole claim perspective

Thank you



About Optum Workers' Compensation and Auto No-Fault Solutions

Optum Workers' Compensation and Auto No-Fault Solutions collaborates with our clients to lower costs while improving health outcomes for the injured persons we serve. Our programs include pharmacy, ancillary, medical bill review, and PPO network solutions, and combine data, analytics, and extensive clinical expertise with innovative technology so injured persons receive safe, appropriate, and cost-effective care throughout the lifecycle of a claim. For more information, email us at expectmore@optum.com.

© 2024 Optum, Inc. All rights reserved. All other brand or product names are trademarks or registered marks of their respective owners. Optum continuously improves our products and services and reserves the right to change specifications without prior notice. CEU-24-2834